Alnylam Financial Statements
Alnylam Financial Information
| Company Type | Public Headquarters |
|---|---|
| Fiscal Year-End | December |
| Annual Report | Company Web Site |
| Investor Relations | Company Web Site |
This data is provided as per license from EDGAR Online
Alnylam Income Statement
| 2007 | 2006 | 2005 | |
|---|---|---|---|
| Revenue ($ mil.) | 50.9 | 26.9 | 5.7 |
| Gross Profit ($ mil.) | -- | -- | -- |
| Operating Income ($ mil.) | (93.2) | (39.5) | (43.5) |
| Total Net Income ($ mil.) | (85.5) | (34.6) | (42.9) |
| Diluted EPS (Net Income) | (2.21) | (1.09) | (1.96) |
Alnylam Quarterly Statements
| Quarter Ending Jun 08 | Quarter Ending Mar 08 | Quarter Ending Dec 07 | |
|---|---|---|---|
| Revenue ($ mil.) | 23.8 | 22.2 | 18.2 |
| Gross Profit ($ mil.) | -- | -- | -- |
| Operating Income ($ mil.) | (12.8) | (4.0) | (2.9) |
| Total Net Income ($ mil.) | (12.8) | (1.2) | 1.7 |
| Diluted EPS (Net Income) | (0.31) | (0.03) | 0.08 |
Alnylam Stock Quote & Chart
11/19/08 16:00:16 EST •
NASDAQ •
20.11
•
 0.0000
•
0.0000 %
|
|---|
|
Quotes delayed 15 minutes for NASDAQ. 20 minutes for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions.
|
Alnylam Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 14.80 | 2.84 | 1.29 |
| Price/Earnings Ratio | -- | 12.30 | 13.49 |
| Price/Book Ratio | 5.99 | 2.24 | 1.23 |
| Price/Cash Flow Ratio | 3.95 | 10.70 | 8.08 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed Alnylam Financial Ratios
Alnylam Competitive Intelligence
| CytRx | Merck | Valeant | |
|---|---|---|---|
| Annual Sales ($ mil.) | 7.5 | 24,197.7 | 872.2 |
| Employees | -- | 59,800 | 3,301 |
| Market Cap ($ mil.) | 51.7 | 68,816.3 | 1,700.1 |
Competitive Landscape
